Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 26 records per page: next > | last >>
pages: 1 2 3 4 5 ... 23 24 25 26 presentations: 1 to 25 of 643
Can the Challenge of NSCLC Resistance Be MET or Will We Not MEK It?
  •  
  • Permission not
    granted for presentation
  •  
  •  
Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations
Shun Lu
Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Can the Challenge of NSCLC Resistance Be MET or Will We Not MEK It?
TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
Lecia Sequist
Massachusetts General Hospital, Boston, MA, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Can the Challenge of NSCLC Resistance Be MET or Will We Not MEK It?
Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study
Suresh S Ramalingam
Emory Univ. Winship Cancer Inst., Atlanta, GA, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Can the Challenge of NSCLC Resistance Be MET or Will We Not MEK It?
Discussant
Roy S Herbst
Yale Cancer Ctr., New Haven, CT, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Modulating the Gut Microbiome to Treat Dysbiosis and Cancer
  •  
  • Permission not
    granted for presentation
  •  
  •  
Cancer therapeutics: A view from the microbiota
Christian Jobin
Univ. of Florida, Gainesville, FL, United States
from AACR Annual Meeting 2019 on March 29, 2019 3:00 PM-5:00 PM
Modulating the Gut Microbiome to Treat Dysbiosis and Cancer
Dynamic monitoring of the dysbiotic microbiome
Jonathan Braun
Mt. Sinai Medical Center, Los Angeles, CA, United States
from AACR Annual Meeting 2019 on March 29, 2019 3:00 PM-5:00 PM
Modulating the Gut Microbiome to Treat Dysbiosis and Cancer
Identification and targeting microbial vulnerabilities
Ami S Bhatt
Stanford Medical School, Stanford, CA, United States
from AACR Annual Meeting 2019 on March 29, 2019 3:00 PM-5:00 PM
Modulating the Gut Microbiome to Treat Dysbiosis and Cancer
Encapsulated fecal transplant: It's not just for Clostridium difficile any more!
Elizabeth L Hohmann
Massachusetts General Hospital, Boston, MA, United States
from AACR Annual Meeting 2019 on March 29, 2019 3:00 PM-5:00 PM
Coevolution of Tumor and Microenvironment in Cancer Metastasis
Systems Immunology and tumor microenvironment: Novel perspectives
Jérôme Galon
INSERM UMRS1138 - Cordeliers Research Ctr., Paris, France
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Coevolution of Tumor and Microenvironment in Cancer Metastasis
Blocking the heterotypic interactions of tumor and TME to control late stage cancer
Dihua Yu
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Coevolution of Tumor and Microenvironment in Cancer Metastasis
  •  
  • Permission not
    granted for presentation
  •  
  •  
Exploring the metastatic niche
Ilaria Malanchi
The Francis Crick Institute, London, United Kingdom
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Coevolution of Tumor and Microenvironment in Cancer Metastasis
Mechanisms underlying polyclonal metastases
Kornelia Polyak
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Vascular-Immune Cell Crosstalk: Implications for Cancer Immunotherapy
Chairperson
Gabriele Bergers
VIB-Center of Cancer Biology, Leuven, Belgium
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Vascular-Immune Cell Crosstalk: Implications for Cancer Immunotherapy
  •  
  • Permission not
    granted for presentation
  •  
  •  
Improving immunotherapy of cancer by normalizing tumor vessels
Rakesh K Jain
Harvard Medical School, Boston, MA, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Vascular-Immune Cell Crosstalk: Implications for Cancer Immunotherapy
Inducing high-endothelial venules in cancer to improve immunotherapy
Gabriele Bergers
VIB-Center of Cancer Biology, Leuven, Belgium
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Vascular-Immune Cell Crosstalk: Implications for Cancer Immunotherapy
  •  
  • Permission not
    granted for presentation
  •  
  •  
Targeting the tumor microenvironment for treatment of chemo-resistant desmoplastic colon cancer
Tatiana Petrova
University of Lausanne, Lausanne, Switzerland
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Vascular-Immune Cell Crosstalk: Implications for Cancer Immunotherapy
  •  
  • Free
  • Unknown permission
    for presentation
  •  
  •  
Clinical development of anti-angiogenic and immune checkpoint blockade combinations
F Stephen Hodi
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Methods for Utilizing the Microbiome in Cancer Epidemiology Research
Introduction
Dominique S Michaud
Tufts University, Boston, MA, United States
from AACR Annual Meeting 2019 on March 30, 2019 1:00 PM-3:00 PM
Methods for Utilizing the Microbiome in Cancer Epidemiology Research
Moving microbiome research into population studies: Need for standardization
Rashmi Sinha
NCI-DCEG, Bethesda, MD, United States
from AACR Annual Meeting 2019 on March 30, 2019 1:00 PM-3:00 PM
Methods for Utilizing the Microbiome in Cancer Epidemiology Research
Microbiome data science and reproducibility with QIIME 2
Joslynn Lee
Howard Hughes Medical Institute, Chevy Chase, MD, United States
from AACR Annual Meeting 2019 on March 30, 2019 1:00 PM-3:00 PM
Methods for Utilizing the Microbiome in Cancer Epidemiology Research
  •  
  • Permission not
    granted for presentation
  •  
  •  
Statistical analysis of microbiome data: Challenges and solutions
Jun Chen
Mayo Clinic, Rochester, MN, United States
from AACR Annual Meeting 2019 on March 30, 2019 1:00 PM-3:00 PM
Methods for Utilizing the Microbiome in Cancer Epidemiology Research
Guild-based analysis for ecological understanding of the causative role of gut microbiota in human health and diseases
Liping Zhao
Rutgers, The State University of New Jersey, New Brunswick, NJ, United States
from AACR Annual Meeting 2019 on March 30, 2019 1:00 PM-3:00 PM
Obesity: The Effects of Local and Systemic Inflammation on Cancer
Introduction: A brief overview of adipose tissue metabolism
Ernst R Lengyel
Univ. of Chicago, Chicago, IL, United States
from AACR Annual Meeting 2019 on March 30, 2019 1:00 PM-3:00 PM
Obesity: The Effects of Local and Systemic Inflammation on Cancer
Paracrine role of mammary adipocytes in breast cancer progression and drug resistance
Catherine Muller
Institut de Pharmacologie et de Biologie Structurale, Toulouse, France
from AACR Annual Meeting 2019 on March 30, 2019 1:00 PM-3:00 PM
Obesity: The Effects of Local and Systemic Inflammation on Cancer
The contribution of adipose fatty acid binding protein in cancer progression
Bing Li
Univ. of Louisville School of Medicine, Louisville, KY, United States
from AACR Annual Meeting 2019 on March 30, 2019 1:00 PM-3:00 PM
<< first | < prev page: of 26 records per page: next > | last >>
pages: 1 2 3 4 5 ... 23 24 25 26 presentations: 1 to 25 of 643